EarningsQ2 2026 Earnings Report
MX:ABBV Q2 2026 EPS Results
Actual EPS$62.58
Consensus EPS$61.81
Beat/MissBeat by +$0.77
One Year Ago EPS$50.92
MX:ABBV Q2 2026 Revenue Results
Actual Revenue$291.28B
Expected Revenue$288.10B
Beat/MissBeat by +$3.19B
YoY Revenue Growth+10.16%
Earnings Announcement Details
QuarterQ2 2026
Date07/31/2026
TimeBefore Open
Conference CallFriday, July 31, 2026
MX:ABBV Upcoming Earnings
AbbVie's next earnings date is estimated for October 23, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ABBV Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: above‑consensus results, double‑digit growth across key franchises (notably SKYRIZI and RINVOQ), multiple regulatory approvals, raised guidance, and a broadened pipeline via the Apogee deal. These positives are tempered by expected declines in legacy products (HUMIRA, IMBRUVICA), modest softness in some aesthetics lines, acquisition‑related dilution and IPR&D expense, and higher interest costs and FX headwinds. On balance the company presented durable growth drivers and ample financial flexibility despite near‑term dilution and known legacy declines.Company Guidance
Earnings and Revenue Beat
Adjusted EPS of $3.65, $0.06 above guidance midpoint; total net revenues nearly $17.0 billion, beating expectations by ~$300 million and reflecting sales growth of 10.2% year-over-year.
Raised Full-Year Guidance
Full-year revenue guidance increased by $300 million (total revision +$600 million since start of year) to approximately $67.6 billion; updated adjusted EPS guidance of $13.87–$14.07 (includes $0.14 anticipated dilution from planned Apogee acquisition).
Strong Immunology Performance (SKYRIZI & RINVOQ)
Immunology revenues nearly $8.8 billion, up 14.6% operationally. SKYRIZI sales $5.5 billion, up 24% operationally; RINVOQ sales >$2.5 billion, up 23.7% operationally. Management expects continued market share gains across psoriasis and IBD and forecasts SKYRIZI global revenues of ~$21.7 billion for 2026.
Neuroscience Momentum
Neuroscience revenues >$3.2 billion, up ~20% operationally. Vraylar nearly $1.1 billion (up ~19%) and Vialev showing sequential growth (Vialev $256 million, up >27% sequential). QLIPTA, Botox Therapeutic, and Ubrellvi delivered double-digit growth in the quarter.
Meaningful Product & Label Approvals
Multiple regulatory wins: US approval of Decnapaz (first ADC in hematology for AbbVie), European approvals for QLIPTA (acute and preventive migraine), Epkinly (2L follicular lymphoma), Bowie (short-acting aesthetics toxin), and European approvals for RINVOQ in vitiligo and alopecia areata (US decisions anticipated).
Pipeline Advancements and Clinical Readouts
Progress across late-stage programs: SKYRIZI SC induction in Crohn's with induction endoscopic response 25 points above placebo (45 points in advanced-therapy‑naive patients); interim combo data showing doubling of endoscopic remission at Week 24; breakthrough designation and advancing tmAbA in CRC and promising tmAbA activity in ovarian/head & neck; etansamig and other hematology programs progressing toward pivotal milestones.
Strategic Acquisition to Bolster Immunology Pipeline
Planned acquisition of Apogee Therapeutics announced to add differentiated dermatology and respiratory assets; AbbVie has secured interim financing, expects close in Q3, and anticipates issuing long-term debt while targeting net leverage of ~2x within 2–3 years.
Robust Margins and Financial Position
Adjusted gross margin of 84.7% of sales, adjusted operating margin of 48.3% (includes 1.7% unfavorable acquired IPR&D impact); adjusted R&D at 13.6% and adjusted SG&A at 21.0% of sales. Company emphasizes strong cash flows and financial flexibility for further BD.
Oncology and ADC Franchise Expansion
Oncology highlights include VENCLEXTA sales of $771 million (up 9.6% operationally), double-digit growth from Elahere, Epkinly, and Amrelis, launch of Decnapaz for BPDCN, and tmAbA progressing into later‑stage development with promising response rates in selected cohorts.
Aesthetics Innovation
Bowie (short-acting toxin) approved in Europe and Canada offering novel patient experience; Botox Cosmetic revenues $728 million, up 3.4% operationally, supporting aesthetics long-term strategy.
MX:ABBV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed